Hipercalcemia

1 Dalemo S, Eggertsen R, Hjerpe P, et al. Long-term follow-up of patients with elevated serum calcium concentrations in Swedish primary care. Scand J Prim Health Care 2012;30:48-54.
2 Lindner G, Felber R, Schwarz C, et al. Hypercalcemia in the ED: prevalence, etiology, and outcome. Am J Emerg Med  013;31:657-60.
3 National Cancer Institute. PDQ® Hypercalcemia. 2013. www.meb.uni-bonn.de/Cancernet/CDR0000062737.html.
4 Potts JT Jr, Jüppner H. Disorders of the parathyroid gland and calcium homeostasis. In: Longo DL, Fauci AS, Kasper DL, Hauser S, eds. Harrison’s principles of internal medicine. 18th ed. McGraw-Hill, 2012:3096-120.
5 Yu N, Donnan PT, Murphy MJ, et al. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol 2009;71:485-93.
6 Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in
Rochester, Minnesota, 1993-2001:  n update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:171-7.
7 Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013;98:1122-9.
8 Gastanaga V, Jain R, Pirolli M, et al. Prevalence of hypercalcemia of malignancy in the United States. Projection methods using oncology electronic health records. Eur J Cancer 2013;49:S302-3.
9 McKay C, Furman WL. Hypercalcemia complicating childhood malignancies. Cancer 1993;72:256-60.
10 Horwitz MJ, Hodak SP, Stewart AF. Non-parathyroid hypercalcemia. In: Rosen CJ, ed.
Primer on the metabolic bone  iseases and disorders of mineral metabolism. 8th ed. Wiley-Blackwell, 2013:562-71.
11 Grieff M, Bushinsky DA. Diuretics and disorders of calcium homeostasis. Semin Nephrol
2011;31:535-41. 12 Wermers RA, Kearns AE, Jenkins GD, et al. Incidence and clinical spectrum of thiazide-associated hypercalcemia. m J Med 2007;120:911.e9-15.
13 Kohut B, Rossat J, Raffoul W, et al. Hypercalcaemia and acute renal failure after major
burns: An under-diagnosed  ondition. Burns 2010;36:360-6.
14 Sato Y, Honda Y, Iwamoto J, et al. Abnormal bone and calcium metabolism in immobilized Parkinson’s disease patients. Mov Disord 2005;20:1598-603.
15 Carnevale V, Dionisi S, Nofroni I, et al. Potential clinical utility of a new IRMA for parathyroid
hormone in postmenopausal  atients with primary hyperparathyroidism. Clin Chem 2004;50:626-31.
16 Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of  he fourth international workshop. J Clin EndocrinolMetab 2014;99:3570-9.
17 Marcocci C, Bollerslev J, Khan AA, et al. Medical management of primary hyperparathyroidism: proceedings of  he fourth International Workshop on the Management of Asymptomatic Primary  Hyperparathyroidism. J Clin Endocrinol Metab 2014;99:3607-18.
18 Minisola S, Romagnoli E, Scillitani A, et al. Hypovitaminosis D in primary hyperparathyroidism: to treat or not to treat? That is the question. J Endocrinol Invest 2014;37:413-4.
19 Streeten EA, Jaimungal S. The differential diagnosis of hypercalcemia. The parathyroids. 3rd ed. Academic Press, 2014:607-16.
20 Minisola S, Romagnoli E, Scarnecchia L, et al. Parathyroid storm: immediate recognition and pathophysiological considerations. Bone 1993;14:703-6.
21 Dionisi S, Minisola S, Pepe J, et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc 2002;77:866-9.
22 Lowe H, Cusano NE, Binkley N, et al. Vitamin D toxicity due to a commonly available “over the counter” remedy from the Dominican Republic. J Clin Endocrinol Metab 2011 ;96:291-5.
23 Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561-9.
24 Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3580-94.
25 Schwarz P, Body JJ, Cap J, et al. The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. Eur J Endocrinol 2014;171:727-35.
26 Minisola S, Romagnoli E, Carnevale V, et al. Acute management of hypercalcemia. In
Bilezikian JP, Marcus R, Levine M, Marcocci, C, Silverberg SJ, Potts J, eds. Parathyroids, basic and clinical concepts. 3rd ed. Academic Press, 2014:617-29.
27 LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008;149:259-63.
28 Kawada K, Minami H, Okabe K, et al. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 2005;35:28-33.
29 Purohit OP, Radstone CR, Anthony C, et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995;72:1289-93.
30 Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-67.
31 Roemer-Bécuwe C, Vigano A, Romano F, et al. Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration. J Pain Symptom Manage 2003;26:843-8.
32 Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis 2014;63:141-7.
33 Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 2014;99:3144-52.
34 Kindgen-Milles D, Kram R, Kleinekofort W, et al. Treatment of severe hypercalcemia using continuous renal replacement therapy with regionalcitrate anticoagulation. ASAIO J2008;54:442-4.